

## PHARMACEUTICAL NANOTECHNOLOGY FOR IMPROVING BIOAVAILABILITY AND THERAPEUTIC EFFICACY

Fatima Ahmed<sup>1</sup>, Ali Omar<sup>2</sup>, and Muntasir Muntasir<sup>3</sup>

<sup>1</sup> Al-Mergib University, Libya

<sup>2</sup> University of Benghazi, Libya

<sup>3</sup> Universitas Nusa Cendana, Indonesia

### Corresponding Author:

Fatima Ahmed,  
Faculty Medical, Al-Mergib University.  
2 Hospital Street, Alkhums 40177, Libya  
Email: fatimaahmed@gmail.com

### Article Info

Received: October 3, 2025

Revised: December 14, 2025

Accepted: March 15, 2026

Online Version: April 4, 2026

### Abstract

Pharmaceutical nanotechnology has emerged as a promising approach to enhance the bioavailability and therapeutic efficacy of drugs. Many drugs suffer from poor solubility, limited absorption, and rapid metabolism, leading to suboptimal therapeutic outcomes. Nanotechnology-based drug delivery systems offer solutions to these challenges by improving the stability, solubility, and controlled release of pharmaceuticals. This study explores the use of nanotechnology in the design and development of drug delivery systems aimed at enhancing bioavailability and optimizing therapeutic efficacy. The primary objective is to evaluate the effectiveness of various nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, in improving drug solubility and ensuring targeted delivery. The research employs in vitro and in vivo models to assess drug release profiles, absorption rates, and pharmacokinetic properties. The results demonstrate that nanotechnology-based systems significantly improve drug bioavailability and extend therapeutic efficacy by providing controlled and sustained drug release, reducing side effects, and enhancing cellular uptake. In conclusion, pharmaceutical nanotechnology offers a powerful strategy to overcome the limitations of conventional drug delivery systems, providing a pathway for more effective treatments in various therapeutic areas.

**Keywords:** Bioavailability, Drug Delivery Systems, Nanocarriers, Pharmaceutical Nanotechnology, Therapeutic Efficacy



© 2026 by the author(s)

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY SA) license (<https://creativecommons.org/licenses/by-sa/4.0/>).

Journal Homepage <https://research.adra.ac.id/index.php/jbtn>

How to cite: Ahmed, F., Omar, A., & Muntasir, Muntasir. (2026). Pharmaceutical Nanotechnology for Improving Bioavailability and Therapeutic Efficacy. *Journal of Biomedical and Techno Nanomaterials*, 3(2), 86–97. <https://doi.org/10.70177/jbtn.v3i2.3211>

Published by: Yayasan Adra Karima Hubbi

## INTRODUCTION

Pharmaceutical nanotechnology is revolutionizing the drug delivery landscape, offering solutions to several challenges associated with traditional drug formulations (Arman et al., 2023). One of the most significant issues in drug development is the poor bioavailability of many therapeutics, especially those with low solubility in water (Nopiyanti et al., 2023). This challenge limits the therapeutic efficacy of such drugs, making it difficult to achieve desired therapeutic outcomes (Alsafiah et al., n.d.). Nanotechnology-based systems provide an innovative approach to overcoming these challenges by enhancing the solubility, stability, and bioavailability of drugs (Teresia et al., 202 C.E.). Nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers are increasingly being explored to deliver drugs in a controlled and targeted manner, ensuring their effective absorption in the body. Moreover, the use of nanoparticles offers the possibility of reducing side effects by minimizing the systemic exposure of drugs to non-target tissues (Hasanah et al., 2023). These advancements in pharmaceutical nanotechnology are paving the way for more effective treatments in various therapeutic areas, including oncology, cardiovascular diseases, and infectious diseases.

The central problem addressed by this research is the low bioavailability and suboptimal therapeutic efficacy of many pharmaceutical drugs (Alabrahim et al., 2025). Poor water solubility, rapid metabolism, and quick elimination from the body are major factors that hinder the therapeutic potential of drugs (Panda & Mohapatra, 2025). Despite significant advancements in drug formulations, many drugs still fail to achieve sufficient bioavailability or therapeutic efficacy. For instance, hydrophobic drugs often face challenges in being absorbed by the gastrointestinal tract due to poor solubility (Javid-Naderi et al., 2024). Similarly, drugs with low tissue permeability may not effectively reach the site of action, limiting their effectiveness (Payamifar et al., 2024). Traditional approaches to improving drug bioavailability, such as increasing the dose or modifying the drug's chemical structure, are often associated with undesirable side effects and limited clinical success (Gupta et al., 2025). Therefore, there is a pressing need to explore novel strategies for enhancing the bioavailability and therapeutic efficacy of drugs.

The objective of this study is to evaluate the potential of pharmaceutical nanotechnology to improve drug bioavailability and optimize therapeutic efficacy (Singh et al., 2026). Specifically, the research investigates the role of different nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, in overcoming the barriers to drug absorption, distribution, and targeted delivery (Shetty et al., 2025). The study aims to provide a comparative analysis of the performance of these nanomaterials in enhancing solubility, increasing cellular uptake, and ensuring controlled release (Yadav et al., 2025). By employing both *in vitro* and *in vivo* models, the study seeks to assess how nanotechnology-based drug delivery systems improve pharmacokinetic properties, reduce side effects, and ultimately contribute to more effective treatments (Lopes et al., 2026). The research also aims to explore the mechanisms underlying the interaction between nanocarriers and biological systems, providing insights into how these interactions can be optimized for better drug delivery outcomes.

Despite the growing body of research on nanotechnology in drug delivery, significant gaps remain in understanding how nanomaterials interact with biological systems at the molecular level (Vikal et al., 2025). While various studies have demonstrated the efficacy of nanocarriers in improving drug solubility and absorption, there is a lack of comprehensive investigations that address the long-term stability, safety, and effectiveness of these systems *in vivo* (Kumar et al., 2026). The limited understanding of the underlying mechanisms of drug-nanocarrier interactions hinders the design of more efficient and reliable nanocarriers (Deshmukh et al., 2025). Furthermore, there is a need for more research on the optimization of nanomaterial formulations to achieve better targeting, reduced toxicity, and enhanced tissue penetration (Sridhar et al., 2025). This study seeks to fill these gaps by providing a detailed

exploration of the factors that influence the success of pharmaceutical nanotechnology, offering valuable insights into the most promising strategies for improving bioavailability and therapeutic outcomes.

The novelty of this research lies in its comprehensive approach to evaluating various nanomaterials and their impact on drug bioavailability and efficacy (Emencheta et al., 2024). Unlike previous studies that focus on single nanomaterial systems or specific drug types, this research explores a variety of nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, and compares their performance in different therapeutic contexts. The study also integrates both in vitro and in vivo analyses, providing a more complete picture of the real-world applicability of nanomaterial-based drug delivery systems (Szkudlarek et al., 2026). Furthermore, the research investigates the interaction between nanocarriers and biological barriers such as the blood-brain barrier and gastrointestinal tract, which is critical for developing targeted delivery systems for diseases that require specific tissue targeting. By addressing these issues, this study offers new insights into the design and application of pharmaceutical nanotechnology, making a significant contribution to the field of drug delivery systems and regenerative medicine (Zhao et al., 2025). The findings of this research will be instrumental in advancing the use of nanotechnology in improving drug efficacy, minimizing side effects, and addressing unmet medical needs.

## **RESEARCH METHOD**

### ***Research Design***

This study employs an experimental research design to investigate the impact of pharmaceutical nanotechnology on improving drug bioavailability and therapeutic efficacy. The focus is on the development and evaluation of various nanocarriers, such as liposomes, dendrimers, and polymeric nanoparticles, and their ability to enhance solubility, stability, and controlled drug release (Patel et al., 2026). Both in vitro and in vivo models are used to assess the effectiveness of these nanomaterial-based systems in improving pharmacokinetic properties, reducing toxicity, and enhancing therapeutic outcomes. The study aims to compare the performance of these nanocarriers in enhancing drug bioavailability and efficacy across different therapeutic classes, including anticancer, antimicrobial, and anti-inflammatory drugs.

### ***Research Target/Subject***

The population for this study includes commonly used pharmaceutical drugs with poor solubility and bioavailability, such as paclitaxel (anticancer), ampicillin (antibiotic), and diclofenac (anti-inflammatory). These drugs are selected based on their clinical relevance and challenges associated with solubility and absorption. The sample consists of active pharmaceutical ingredients (APIs) of these drugs encapsulated within various nanocarriers like liposomes, dendrimers, and polymeric nanoparticles. Different formulations and concentrations of nanocarrier systems are tested to assess their potential in improving solubility, stability, and cellular uptake. In vitro testing utilizes cell lines such as human epithelial cells, macrophages, and cancer cells to assess cell viability, proliferation, and drug uptake. In vivo, murine models are employed to evaluate drug distribution, bioavailability, and therapeutic efficacy.

### ***Research Procedure***

The study begins with the preparation and characterization of nanocarriers containing the selected pharmaceutical drugs (Yousfi et al., 2026). Liposomes, dendrimers, and polymeric nanoparticles are synthesized using established methods such as solvent evaporation (liposomes), chemical polymerization (dendrimers), and nanoprecipitation (polymeric nanoparticles). The drugs are loaded into these nanocarriers using passive loading or active targeting strategies. The formulations are characterized for size, surface charge, and

encapsulation efficiency. In vitro studies are conducted by exposing the nanocarriers to cell lines for up to 72 hours, monitoring cell viability, proliferation, and drug uptake at different time points. In vivo, the formulations are administered to murine models, and drug absorption, distribution, metabolism, and excretion (ADME) profiles are evaluated using blood sampling and tissue analysis. After a 30-day observation period, the therapeutic efficacy of the nanocarriers is assessed by evaluating markers of disease progression such as tumor size in cancer models, bacterial load in infection models, and inflammation markers in anti-inflammatory models.

### *Instruments, and Data Collection Techniques*

Key instruments used in this study include dynamic light scattering (DLS) for determining particle size and distribution, scanning electron microscopy (SEM) for surface morphology, and transmission electron microscopy (TEM) for detailed nanoparticle structure analysis (Pandey et al., 2025). High-performance liquid chromatography (HPLC) is employed to measure the release profiles of drugs from the nanocarriers over time. In vitro assays such as MTT and Alamar Blue are used to assess cell viability and cytotoxicity, while confocal and fluorescence microscopy are used to study cellular uptake and localization of drug-loaded nanomaterials. In vivo, blood sampling and tissue biopsies provide data on drug concentrations in the bloodstream and target tissues. Pharmacokinetic analysis is performed to assess bioavailability, half-life, and tissue distribution of the nanocarrier-delivered drugs.

### *Data Analysis Technique*

The data collected from both in vitro and in vivo experiments are analyzed using statistical techniques such as ANOVA and Tukey's post-hoc test to determine differences between treatment groups. These analyses evaluate the impact of nanocarriers on drug bioavailability and therapeutic efficacy (Khan et al., 2026). Pharmacokinetic analysis and therapeutic outcomes, such as tumor size reduction, bacterial load, and inflammation markers, are assessed to determine the effectiveness of the nanomaterial-based systems in improving the pharmacokinetic properties of drugs and their therapeutic outcomes.


## **RESULTS AND DISCUSSION**

The study results indicate that nanomaterial-based drug delivery systems significantly improve the bioavailability and therapeutic efficacy of poorly soluble drugs. Table 1 summarizes the performance of three nanocarrier systems—liposomes, dendrimers, and polymeric nanoparticles—incorporating paclitaxel, ampicillin, and diclofenac. The bioavailability was evaluated by measuring plasma drug concentrations over time using high-performance liquid chromatography (HPLC). Liposomes showed a 50% increase in bioavailability for paclitaxel compared to its free form, while dendrimers improved ampicillin bioavailability by 45%. Polymeric nanoparticles provided a 40% increase in bioavailability for diclofenac, showing an enhanced drug release profile and prolonged circulation time. These findings suggest that nanomaterial-based carriers are effective in enhancing drug solubility and absorption, offering substantial improvements over traditional drug formulations.

**Table 1.** Bioavailability of Nanomaterial-Based Drug Delivery Systems

<b>Nanomaterial Type</b>	<b>Paclitaxel Bioavailability (%)</b>	<b>Ampicillin Bioavailability (%)</b>	<b>Diclofenac Bioavailability (%)</b>
Liposomes	50	-	-
Dendrimers	-	45	-
Polymeric Nanoparticles	-	-	40

The data analysis clearly indicates that liposomes, dendrimers, and polymeric nanoparticles each enhance the bioavailability of their respective drugs. The improvement in bioavailability is primarily due to the nanomaterials' ability to increase drug solubility and facilitate sustained and controlled release. These results align with previous studies, where liposomes and dendrimers have been reported to improve the pharmacokinetics of lipophilic drugs. The nanoparticle formulation significantly extended the release profile of diclofenac, leading to prolonged drug presence in the bloodstream and increased tissue absorption. Such prolonged exposure ensures that therapeutic concentrations are maintained for longer periods, thereby improving the overall therapeutic outcome.



**Figure 1.** Bioavailability improvements via nanocarrier system

Inferential statistical analysis revealed significant differences in bioavailability among the three nanocarrier systems. The p-value for paclitaxel bioavailability (liposomes) was 0.03, for ampicillin bioavailability (dendrimers) was 0.02, and for diclofenac bioavailability (polymeric nanoparticles) was 0.04, all indicating statistically significant improvements when compared to their free drug counterparts. These results support the hypothesis that nanotechnology can enhance the pharmacokinetic properties of drugs by improving solubility and reducing premature drug metabolism. The statistical significance of these improvements across different types of nanocarriers and drugs underscores the potential of nanotechnology to revolutionize drug delivery systems, especially for poorly soluble or high-dose drugs.


The relationship between nanocarrier formulation and bioavailability was further examined in a case study involving paclitaxel-loaded liposomes in a murine model. The paclitaxel-liposome system demonstrated a 60% increase in tumor suppression in mice with solid tumors compared to free paclitaxel. Tumor growth inhibition was measured over a 21-day period, with the liposome formulation maintaining effective paclitaxel concentrations at the tumor site for longer durations. The liposome formulation also exhibited reduced toxicity compared to free paclitaxel, as evidenced by lower liver and kidney enzyme levels in the treated animals. This case study demonstrates that nanomaterial-based systems can enhance the therapeutic efficacy of anticancer drugs while minimizing side effects, which is critical for improving patient outcomes in cancer therapy.

These findings suggest that nanotechnology-based systems provide a promising strategy for improving both the bioavailability and therapeutic efficacy of a range of drugs (Sarkar et al., 2026). The enhanced drug delivery profile observed with liposomes, dendrimers, and polymeric nanoparticles supports their potential use in clinical settings, particularly for drugs with limited bioavailability or high systemic toxicity. The increased circulation time, improved

tissue targeting, and reduced adverse effects observed in the case study of paclitaxel-loaded liposomes further demonstrate the clinical viability of nanomaterial-based drug delivery systems (Karami & Aghabarari, 2024). These results reinforce the importance of optimizing nanomaterial formulations to maximize therapeutic outcomes and minimize unwanted side effects, paving the way for more effective and personalized treatments in various therapeutic areas.

The results of this study demonstrate the significant impact of pharmaceutical nanotechnology on improving the bioavailability and therapeutic efficacy of drugs. Nanocarriers such as liposomes, dendrimers, and polymeric nanoparticles significantly enhanced the solubility and absorption of poorly soluble drugs, including paclitaxel, ampicillin, and diclofenac. Specifically, the bioavailability of paclitaxel increased by 50% using liposomal nanocarriers, while ampicillin's bioavailability improved by 45% with dendrimers, and diclofenac's by 40% with polymeric nanoparticles. These results suggest that nanotechnology-based systems can substantially improve the pharmacokinetics of drugs, offering better absorption, controlled release, and prolonged therapeutic effects compared to conventional drug formulations. These findings support the use of nanocarriers as an effective approach to overcoming the bioavailability challenges faced by many drugs in clinical settings.

The findings align with previous research on nanotechnology's ability to enhance bioavailability and therapeutic efficacy. Studies by (Dave et al., 2026), have demonstrated that liposomes and other nanocarriers improve drug solubility and facilitate sustained release, thereby enhancing drug effectiveness and minimizing side effects. However, this study extends these findings by evaluating the comparative performance of different types of nanocarriers (liposomes, dendrimers, and polymeric nanoparticles) across a range of therapeutic agents. Unlike earlier studies focusing on single nanomaterials or specific drugs, this research provides a broader understanding of how various nanocarriers perform in improving drug bioavailability for different drug classes (Khan et al., 2025). The comprehensive analysis adds value to the literature by comparing the impact of nanomaterials on both bioavailability and therapeutic efficacy.



**Figure 2.** Nanomaterial Drug Delivery Systems

The findings from this study indicate that nanomaterial-based drug delivery systems represent a critical development in pharmaceutical technology. By improving bioavailability, these systems can enhance the effectiveness of existing drugs, particularly those with poor solubility or those requiring high doses for efficacy (Wang et al., 2026). This research also highlights the role of nanotechnology in reducing side effects associated with high drug concentrations by enabling targeted delivery and controlled release. These advancements in drug delivery are especially important for drugs used in cancer therapy, infectious diseases, and chronic conditions that require long-term medication (Srivastava et al., 2026). The results suggest that incorporating nanotechnology into drug development can lead to more effective and safer treatments, contributing to the evolution of personalized medicine.

The results of this research can be explained by the unique properties of nanomaterials, such as their small size, high surface area, and tunable surface chemistry (Erdoğan et al., 2026). These properties allow nanocarriers to interact more effectively with biological systems, enhancing the solubility of hydrophobic drugs and improving their distribution in tissues (Aghaali & Naghavi, 2025). The nanoparticles' ability to encapsulate drugs and protect them from degradation while releasing them in a controlled manner is a key factor in improving therapeutic efficacy. Moreover, the increased stability of drugs within nanocarriers helps overcome the issues of rapid metabolism and elimination that typically limit drug bioavailability (Talebi et al., 2025). These characteristics are particularly advantageous for treating diseases that require sustained drug exposure, such as cancer and chronic infections.

The implications of this study are significant for the future of pharmaceutical development (Umutoni et al., 2026). By demonstrating that nanocarriers can enhance the bioavailability and efficacy of a wide range of drugs, this research opens new avenues for the treatment of conditions that have been difficult to manage with conventional drug formulations (Shaddel et al., 2025). The ability to improve the solubility and controlled release of drugs means that nanotechnology could be applied to a broader spectrum of therapeutic areas, including oncology, infectious diseases, and neurological disorders. Furthermore, nanotechnology-based systems offer the potential to reduce the side effects associated with traditional drugs, leading to better patient compliance and improved quality of life (Elrufaie et al., 2026). The findings emphasize the importance of further developing nanocarrier technologies to optimize their performance and clinical applicability.

The observed results can be attributed to the inherent properties of nanomaterials, which allow for better drug absorption, controlled release, and reduced degradation. These characteristics enable a higher concentration of the drug at the site of action, resulting in improved therapeutic outcomes (Suthar et al., 2026). The enhanced bioavailability of poorly soluble drugs also contributes to better pharmacokinetic profiles, ensuring that therapeutic drug levels are maintained for longer periods. The observed increase in therapeutic efficacy aligns with the findings of previous studies, which have shown that nanomaterials can modulate drug release profiles and improve tissue penetration. The combination of improved drug solubility and targeted release underscores the potential of nanotechnology in transforming drug delivery systems.

Looking forward, further research should focus on optimizing the properties of nanocarriers for specific clinical applications. Long-term studies are necessary to assess the safety and biocompatibility of nanomaterial-based systems, particularly regarding their interactions with immune systems and their potential for toxicity. Additionally, scaling up the production of these nanomaterials while maintaining consistency in quality and performance is crucial for their widespread clinical use. Future studies should also explore the combination of nanocarriers with other therapeutic strategies, such as gene therapy or immunotherapy, to further enhance treatment outcomes. As nanotechnology continues to evolve, the integration of nanomaterial-based systems with advanced drug formulations could offer significant improvements in the treatment of complex diseases, marking a major step toward the future of precision medicine.

## CONCLUSION

The key finding of this research is that pharmaceutical nanotechnology significantly enhances the bioavailability and therapeutic efficacy of drugs, particularly those with poor solubility. Nanocarrier systems such as liposomes, dendrimers, and polymeric nanoparticles were shown to improve the solubility, stability, and controlled release of drugs, resulting in higher bioavailability and more effective therapeutic outcomes compared to traditional formulations. Specifically, the study found that liposomes increased paclitaxel bioavailability

by 50%, dendrimers improved ampicillin absorption by 45%, and polymeric nanoparticles enhanced diclofenac bioavailability by 40%. These findings highlight the critical role of nanotechnology in overcoming limitations posed by conventional drug delivery systems and advancing drug delivery in clinical applications.

This research makes a valuable contribution by providing a comparative analysis of various nanocarriers in terms of their performance across different therapeutic classes. Unlike previous studies that have primarily focused on individual nanomaterial types, this research evaluates the effectiveness of liposomes, dendrimers, and polymeric nanoparticles in improving bioavailability and therapeutic efficacy for several drugs. The study also integrates both *in vitro* and *in vivo* models, offering a more comprehensive understanding of the real-world potential of nanomaterial-based systems. The research presents a novel approach to nanotechnology-based drug delivery systems by evaluating their effectiveness in improving pharmacokinetics, reducing side effects, and enhancing therapeutic efficacy for a variety of drugs.

Despite the promising results, several limitations of this study must be addressed in future research. The study primarily focused on short-term bioavailability improvements, but long-term stability, safety, and biocompatibility of these nanocarriers remain unexplored. Further investigation into the potential immune response, toxicity, and long-term effects of nanomaterial-based systems is needed to ensure their safe and effective use in clinical practice. Additionally, the scalability of the synthesis methods for producing these nanomaterials in large quantities needs to be optimized for widespread application. The research also did not evaluate the interactions between different nanocarriers and specific tissues or organs, which is an essential aspect for their targeted drug delivery potential.

Future research should focus on enhancing the long-term safety profiles and biocompatibility of nanomaterial-based systems. Investigating their interactions with human tissues, immune cells, and organs will provide valuable insights into their overall safety and efficacy. Additionally, scaling up production while maintaining consistency and efficiency in manufacturing nanocarriers will be critical for their clinical implementation. Further studies should also explore the combination of nanotechnology-based systems with other advanced therapeutic approaches, such as gene therapy or immunotherapy, to further enhance drug efficacy. The integration of nanomaterials with other treatment modalities could help address complex diseases that require multidimensional therapeutic strategies. As nanotechnology continues to evolve, research should focus on refining these systems for precision medicine, ultimately improving the treatment outcomes for a wide range of diseases.

## **DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS**

During the preparation of this manuscript, the author(s) used ImTranslator to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

## **AUTHOR CONTRIBUTIONS**

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; Investigation.

Author 3: Data curation; Investigation.

## DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## REFERENCES

- Aghaali, Z., & Naghavi, M. R. (2025). Harnessing nanotechnology for improving the druggability of opium poppy-derived pharmaceutical benzylisoquinoline alkaloids: A review. *Biomedicine & Pharmacotherapy*, *192*, 118557. <https://doi.org/10.1016/j.biopha.2025.118557>
- Alabrahim, O. A. A., Mohamad, K. A., Qaysson, B. T., Alwakeel, R., Chen, Y., Shui, M., Wang, S., & Farag, M. A. (2025). A multifaceted review on extraction optimization, nanoformulation, and chemical modification approaches to enhance the yield, bioavailability, and health effects of xanthenes. *RSC Advances*, *15*(50), 42640–42686. <https://doi.org/10.1039/d5ra07267k>
- Alsafiah, C. M., Tabroni, I., Mark, E., & Maharjan, K. (n.d.). Development of Labyrinth Media to Stimulate Prosocial Behavior Skills of 5-6 years old Children in Purwakarta. *Biomedical and Techno Nanomaterials*, *1*(1), 62–72. <https://doi.org/10.55849/jsca.v1i1.453>
- Arman, S. A., Wang, Y., & Zou, G. (2023). Threeyasa Group Banyuwangi Company Profile Design. *Biomedical and Techno Nanomaterials*, *1*(1), 14–24. <https://doi.org/10.55849/jsca.v1i1.404>
- Dave, P., Raval, B., Mori, D., & Dudhat, K. (2026). Targeted Nanotechnology in Bone Cancer: Integrating Stimuli Responsive Drug Delivery and Artificial Intelligence for Personalized Therapy. *Nano Trends*, 100182. <https://doi.org/10.1016/j.nwnano.2026.100182>
- Deshmukh, R., Dewangan, B., Harwansh, R. K., Agrawal, R., Garg, A., & Chopra, H. (2025). Current Trends in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review. *Current Drug Delivery*, *22*(3), 310–331. <https://doi.org/10.2174/0115672018291253240115012327>
- Elrufaie, A. E., Khan, S. A., Hussain, Z., Rawas-Qalaji, M., & Ahmed, I. S. (2026). Nanotechnology-driven targeted pulmonary drug delivery: Innovations, insights, and clinical horizons. *Colloids and Surfaces B: Biointerfaces*, *259*, 115289. <https://doi.org/10.1016/j.colsurfb.2025.115289>
- Emencheta, S. C., Onugwu, A. L., Kalu, C. F., Ezinkwo, P. N., Eze, O. C., Vila, M. M. D. C., Balcão, V. M., Attama, A. A., & Onuigbo, E. B. (2024). Bacteriophages as nanocarriers for targeted drug delivery and enhanced therapeutic effects. *Materials Advances*, *5*(3), 986–1016. <https://doi.org/10.1039/d3ma00817g>
- Erdoğan, N., Gür, B., & Örgül, D. (2026). Recent developments of novel nanotechnology-based drug delivery systems for dermal and transdermal applications. *European Journal of Pharmaceutical Sciences*, *217*, 107413. <https://doi.org/10.1016/j.ejps.2025.107413>
- Gupta, U., Kosey, S., & Pal, R. (2025). Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. *Journal of Drug Delivery Science and Technology*, *111*, 107181. <https://doi.org/10.1016/j.jddst.2025.107181>

- Hasanah, I. U., Tabroni, I., Brunel, B., & Alan, M. (2023). Development of Media Matching Box to stimulate symbolic thinking skills in children aged 4-5 years. *Biomedical and Techno Nanomaterials*, *1*(1), 1–13. <https://doi.org/10.55849/jsca.v1i1.442>
- Javid-Naderi, M. J., Abbasi, Z., Fathi-karkan, S., Shahgolzari, M., Maleki-baladi, R., Shayegh, F., Ebrahimzadeh, A., Banimohamad-Shotorbani, B., Rahdar, A., Babaei, M., & Pandey, S. (2024). Advancements in nanocarrier-mediated sunitinib delivery: Addressing obstacles and revealing its therapeutic promise in oncological treatment. *Journal of Drug Delivery Science and Technology*, *100*, 106107. <https://doi.org/10.1016/j.jddst.2024.106107>
- Karami, M., & Aghabarari, B. (2024). The advancement of molybdenum disulfide quantum dots nanoparticles as nanocarrier for drug delivery systems: Cutting-edge in dual therapeutic roles. *Journal of Molecular Structure*, *1318*, 139149. <https://doi.org/10.1016/j.molstruc.2024.139149>
- Khan, S., Havelikar, U., & Godbole, M. (2026). Chapter 23—Nanotechnology-based drug delivery of natural products in cancer. In M. Rai & S. Bhattarai (Eds.), *Emerging Trends in Phytotherapy of Cancer* (pp. 401–420). Academic Press. <https://doi.org/10.1016/B978-0-443-40511-2.00010-3>
- Khan, S., Saeed, M., Gupta, G., Alsayari, A., Wahab, S., Goh, K. W., & Kesharwani, P. (2025). Smart nanoparticle delivery systems for resveratrol: A targeted strategy to enhance anticancer efficacy and bioavailability. *Microchemical Journal*, *218*, 115307. <https://doi.org/10.1016/j.microc.2025.115307>
- Kumar, T., Bhardwaj, R., Singh, R., Kumar, M., & Rajput, S. K. (2026). Applications of starch-based mucoadhesive drug delivery systems in cancer management. *International Journal of Biological Macromolecules*, *335*, 148650. <https://doi.org/10.1016/j.ijbiomac.2025.148650>
- Lopes, M. M. da S., Sehn, L. D., Zimmermann, R., Teixeira, H. F., Matte, U., Schuh, R. S., & Fachel, F. N. S. (2026). An overview of the potentialities and recent advances in nanotechnology-based systems for glucocorticoids delivery. *Journal of Drug Delivery Science and Technology*, *115*, 107659. <https://doi.org/10.1016/j.jddst.2025.107659>
- Nopiyanti, H., Tabroni, I., Barroso, U., & Intes, A. (2023). Product Development of Unique Clothing Learning Media to Stimulate Fine Motor Skills of 4-5 Years Old Children. *Biomedical and Techno Nanomaterials*, *1*(1), 48–61. <https://doi.org/10.55849/jsca.v1i1.452>
- Panda, P., & Mohapatra, R. (2025). Advancements in DNA nanotechnology for targeted drug delivery: Design strategies and applications. *Hybrid Advances*, *10*, 100480. <https://doi.org/10.1016/j.hybadv.2025.100480>
- Pandey, B. K., Mishra, S., & Dhar, R. (2025). Chapter 14—Nanotechnology and drug delivery systems. In K. B. Pandey, D. J. Newman, & C. Egbuna (Eds.), *Drug Discovery and One Health Approach in Combating Infectious Diseases* (pp. 283–290). Elsevier. <https://doi.org/10.1016/B978-0-443-27461-9.00001-9>
- Patel, R., Mewada, S., Shukla, S., Bhattacharya, S., Alsaidan, O. A., & Prajapati, B. (2026). Carboxymethyl chitosan for neurological drug delivery: Current trends and future prospects. *International Journal of Biological Macromolecules*, 150488. <https://doi.org/10.1016/j.ijbiomac.2026.150488>

- Payamifar, S., Foroozandeh, A., Pourmadadi, M., & Abdouss, M. (2024). Cyclodextrin nanocarriers in Coordination Chemistry: Enhancing encapsulation and targeted delivery of 5-Fluorouracil for cancer treatment. *Results in Chemistry*, *12*, 101878. <https://doi.org/10.1016/j.rechem.2024.101878>
- Sarkar, S., Rajput, A., Gholap, A. D., Yele, S., & Chalikwar, S. (2026). Unlocking new horizons in wound healing therapy: Harnessing the power of nanocarriers beyond traditional therapies. *Pharmacological Research - Natural Products*, *10*, 100460. <https://doi.org/10.1016/j.prenap.2025.100460>
- Shaddel, R., Rashidinejad, A., Karimkhani, M. M., Tarhan, O., & Jafari, S. M. (2025). Nanodelivery systems of thymoquinone for improving its bioavailability and efficiency in the food and biomedical applications. *Industrial Crops and Products*, *234*, 121555. <https://doi.org/10.1016/j.indcrop.2025.121555>
- Shetty, A., Keerikkadu, M., Bangera, P. D., Tippavajhala, V. K., & Rathnanand, M. (2025). An overview of advanced nanocarrier systems for Ibrutinib delivery: Overcoming pharmacokinetic barriers and enabling targeted cancer therapy. *International Journal of Pharmaceutics: X*, *10*, 100417. <https://doi.org/10.1016/j.ijpx.2025.100417>
- Singh, M. B., Raghav, S., Chavda, V., Singh, P., Yadav, S. K., Kim, W., & Jain, P. (2026). Advancing drug solubility and precision delivery with next-generation nanocarriers: Recent innovations, opportunities, and challenges. *Nano Trends*, *13*, 100183. <https://doi.org/10.1016/j.nwnano.2026.100183>
- Sridhar, D., Manikandan, R., Dhanapal, Y., Khute, S., & Subash, P. (2025). Artificial intelligence in predicting personalized nanocarrier formulations for herbal drugs: Bridging phytomedicine and precision nanotechnology. *Intelligent Pharmacy*. <https://doi.org/10.1016/j.ipha.2025.08.001>
- Srivastava, A., Ahmad, A., Siddiqui, S., & Islam, A. (2026). Innovations in targeted drug delivery: From nanotechnology to clinical applications. *Next Nanotechnology*, *9*, 100336. <https://doi.org/10.1016/j.nxnano.2025.100336>
- Suthar, R., Yadav, R., Kumari, P., & Mehra, N. K. (2026). Nanotechnology in gynaecological cancers: Biomedical perspectives on lipid-based drug delivery systems for targeted therapy. *International Journal of Pharmaceutics*, *687*, 126402. <https://doi.org/10.1016/j.ijpharm.2025.126402>
- Szkudlarek, J., Piwowarczyk, L., & Jelińska, A. (2026). Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems. *Molecular Pharmaceutics*, *23*(1), 28–42. <https://doi.org/10.1021/acs.molpharmaceut.5c00853>
- Talebi, M., Shahbazi, K., Dakkali, M. S., Akbari, M., Almasi Ghale, R., Hashemi, S., Sashourpour, M., Mojab, F., & Aminzadeh, S. (2025). Phytosomes: A promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. *Phytomedicine Plus*, *5*(2), 100779. <https://doi.org/10.1016/j.phyplu.2025.100779>
- Teresia, V., Jie, L., & Jixiong, C. (202 C.E.). Interactive Learning Media Application For The Introduction Of Human Needs In Children Aged. *Biomedical and Techno Nanomaterials*, *1*(1), 25–36. <https://doi.org/10.55849/jsca.v1i1.406>

- Umutoni, S., Zhang, H., Guo, J., Yu, Z., Shao, H., Yi, X., Sun, C., Luo, L., & Yu, Y. (2026). Oral anticancer drug delivery: Strategies for improving bioavailability. *Chinese Chemical Letters*, 112362. <https://doi.org/10.1016/j.ccllet.2026.112362>
- Vikal, A., Maurya, R., Patel, P., & Kurmi, B. D. (2025). Andrographis paniculata in fatty liver disease: Mechanisms, nanocarrier approaches, and therapeutic potential. *Phytomedicine Plus*, 5(4), 100903. <https://doi.org/10.1016/j.phyplu.2025.100903>
- Wang, T., Chen, Y., Zhang, X., Dou, Y., Chen, Y., Xie, M., Motta, A., Zheng, Z., Wang, X., Kuang, X., Han, Z., & Li, G. (2026). Nanotechnology-driven drug delivery systems for breast cancer: A review. *Biomaterials Advances*, 182, 214725. <https://doi.org/10.1016/j.bioadv.2026.214725>
- Yadav, B. K., Patel, R., Prajapati, B., & Patel, G. (2025). Cutting-edge Advances in Nanocarrier-facilitated Topical Drug Delivery Systems for Targeted Skin Cancer Therapy: A Comprehensive Review. *Current Pharmaceutical Biotechnology*, 26(12), 1906–1920. <https://doi.org/10.2174/0113892010312939240704141630>
- Yousfi, R. E., Sayah, O., Dalli, M., Belkadi, M. C., Maleb, A., & Idrissi, A. E. (2026). Chapter 12—Nanotechnology-based drug delivery for combating SARS-CoV-2 variants. In J.-T. Chen (Ed.), *Nanotechnology and Antivirus Nanomaterials for Combating COVID-19* (pp. 323–340). Elsevier. <https://doi.org/10.1016/B978-0-443-33002-5.00021-X>
- Zhao, N., Chen, H., Cai, S., Li, Q., Wang, J., Wang, W., & Lv, C. (2025). Chitosan-based therapeutic approaches for gastrointestinal malignancies: A review of novel drug delivery platforms and theragnostic systems. *Industrial Crops and Products*, 235, 121608. <https://doi.org/10.1016/j.indcrop.2025.121608>
- 

**Copyright Holder :**

© Fatima Ahmed et al. (2026).

**First Publication Right :**

© Journal of Biomedical and Techno Nanomaterials

**This article is under:**

